Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Anterios On Deck For Ipo - Anterios (pending:ante) | Seeking Alpha

ETF Hub Anterios on deck for IPO May 4 2015, 13:09 ET | About: Anterios (ANTE) | By: Douglas W. House , SA News Editor New York, NY-based Anterios (Pending: ANTE ) is set for its IPO of 3.9M shares of common stock at $12 - 14. The clinical stage biopharmaceutical firm develops botulinum products for therapeutic and aesthetic applications. Botulinum toxin type A (botulinum) is currently almost a $3B global market, led by Allergan's ( AGN ) Botox. The firm's lead product candidate is the Phase 2-stage ANT-1207 , a topical formulation prevent underarm sweating of botulinum for the treatment of primary axillary hyperhidrosis (excessive underarm sweating), facial acne and lateral canthal lines (crow's feet wrinkles). Its second candidate is AI-09, an injectable botulinum that will be packaged as a ready-to-use liquid. other Currently available injectable botulinum products are lyophilized which require reconstitution prior to use.
For the original version including any supplementary images or video, visit http://seekingalpha.com/news/2482986-anterios-on-deck-for-ipo?source=feed_news_all

Don't be the product, buy the product!